Quinoline derivatives with other anti-viral agents
View Patent ↗Compositions and methods for the treatment or prophylaxis of viral and other infections (e.g., coronavirus) are provided. The compositions typically comprise a quinoline derivative and an additional anti-viral agent. Incorporations of these agents into fabrics for use as filtration devices which forestall infection is also disclosed.
1. A pharmaceutical composition comprising one or more pharmaceutically acceptable carrier, diluents, or excipients and a therapeutically effective amount of a quinoline derivative and optionally an anti-viral agent;
wherein the quinoline derivative is selected from chloroquine, hydroxychloroquine, quinine, or quinidine, enantiomers, mixtures of enantiomers, racemates, thereof; or pharmaceutically acceptable salts of any of the foregoing; and
wherein the anti-viral agent is selected from pyrithione, hinokitiol, tetracycline, doxycycline, azithromycin, and zinc; or tautomers, enantiomers, mixtures of enantiomers, racemates, thereof or pharmaceutically acceptable salts of any of the foregoing.
2. The pharmaceutical composition according to claim 1 , wherein the composition is in a form suitable for oral administration.
3. The pharmaceutical composition according to claim 1 , wherein the composition is in a form suitable for intranasal administration.
4. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in the form of a spray, ointment, foam, solution for producing steam, aerosol, liquid drops, nasal spray, oral spray, mouthwash, mouth rinse, eye drops, ear drops, syrup, or tonic.
5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition has a weight ratio of the quinoline derivative to the anti-viral agent of 100:1 to 1:100.
6. A fabric comprising a quinoline derivative and/or an anti-viral agent;
wherein the anti-viral agent is selected from pyrithione, hinokitiol, tetracycline, doxycycline, azithromycin, and zinc; or tautomers, enantiomers, mixtures of enantiomers, racemates, thereof, or pharmaceutically acceptable salts of any of the foregoing;
wherein the quinoline derivative is selected from chloroquine, hydroxychloroquine, quinine, or quinidine, enantiomers, mixtures of enantiomers, racemates, thereof; or pharmaceutically acceptable salts of any of the foregoing; and
wherein the anti-viral agent and/or quinoline derivative is impregnated in the fabric.
7. The fabric according to claim 6 , wherein the fabric is cloth.
8. The fabric according to claim 6 , wherein the fabric comprises from 0.01% to 10% of the anti-viral agent or quinoline derivative by weight of the fabric.
9. The fabric according to claim 6 , wherein the fabric comprises from about 0.1% to 20% of the anti-viral agent and quinoline derivative by weight of the fabric.
10. The fabric according to claim 6 , wherein the fabric has a weight ratio of the quinoline derivative to the anti-viral agent of 100:1 to 1:100.
11. The fabric according to claim 6 , wherein the fabric has a thickness from 0.1 mm to 5 mm.
12. The fabric according to claim 6 , wherein the fabric has an air permeability of more than 5 cm 3 /cm 2 /sec.
13. A facemask having a breathing piece such that air passes through the breathing piece when a user is breathing; wherein the breathing piece comprises the fabric according to claim 6 , and the air passes through the fabric or moves along the surface of the fabric.